How to buy LivaNova stock | $83.54

LivaNova PLC is a medical devices business based in the US. LivaNova shares (LIVN) are listed on the NASDAQ and all prices are listed in US Dollars. LivaNova employs 4,000 staff and has a trailing 12-month revenue of around 0.00.

LivaNova stock price (NASDAQ: LIVN)

Use our graph to track the performance of LIVN stocks over time.

LivaNova shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$83.54
52-week range	$41.07 - $90.25
50-day moving average	$82.63
200-day moving average	$78.04
Wall St. target price	$95.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-5.41

Buy LivaNova shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy LivaNova stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of LivaNova PLC by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

LivaNova price performance over time

Historical closes compared with the close of $83.54 from 2021-05-28

1 week (2021-07-22)	N/A
1 month (2021-07-02)	0.58%
3 months (2021-04-30)	-1.57%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Is LivaNova under- or over-valued?

Valuing LivaNova stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LivaNova's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

LivaNova's PEG ratio

LivaNova's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0239. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LivaNova's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

LivaNova's EBITDA

LivaNova's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $46.3 million.

The EBITDA is a measure of a LivaNova's overall financial performance and is widely used to measure a its profitability.

LivaNova financials

Revenue TTM	$1 billion
Gross profit TTM	$605.3 million
Return on assets TTM	-0.34%
Return on equity TTM	-31.94%
Profit margin	-37.15%
Book value	$21.24
Market capitalisation	$4.2 billion

TTM: trailing 12 months

Shorting LivaNova shares

There are currently 2.1 million LivaNova shares held short by investors – that's known as LivaNova's "short interest". This figure is 13.7% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting LivaNova shares can be evaluated.

LivaNova's "short interest ratio" (SIR)

LivaNova's "short interest ratio" (SIR) is the quantity of LivaNova shares currently shorted divided by the average quantity of LivaNova shares traded daily (recently around 212843.55644356). LivaNova's SIR currently stands at 10.01. In other words for every 100,000 LivaNova shares traded daily on the market, roughly 10010 shares are currently held short.

However LivaNova's short interest can also be evaluated against the total number of LivaNova shares, or, against the total number of tradable LivaNova shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case LivaNova's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 LivaNova shares in existence, roughly 40 shares are currently held short) or 0.0436% of the tradable shares (for every 100,000 tradable LivaNova shares, roughly 44 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against LivaNova.

Find out more about how you can short LivaNova stock.

LivaNova share dividends

We're not expecting LivaNova to pay a dividend over the next 12 months.

LivaNova share price volatility

Over the last 12 months, LivaNova's shares have ranged in value from as little as $41.07 up to $90.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LivaNova's is 0.8945. This would suggest that LivaNova's shares are less volatile than average (for this exchange).

LivaNova overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.

Frequently asked questions

What percentage of LivaNova is owned by insiders or institutions?
Currently 0.453% of LivaNova shares are held by insiders and 103.25% by institutions. How many people work for LivaNova?
Latest data suggests 4,000 work at LivaNova. When does the fiscal year end for LivaNova?
LivaNova's fiscal year ends in December. Where is LivaNova based?
LivaNova's address is: 20 Eastbourne Terrace, London, United Kingdom, W2 6LG What is LivaNova's ISIN number?
LivaNova's international securities identification number is: GB00BYMT0J19 What is LivaNova's CUSIP number?
LivaNova's Committee on Uniform Securities Identification Procedures number is: G5509L101